# US 2016/0250320 A1 · Immunoregulatory peptides and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250320 A1
- Document ID: US20160250320A1
- Status: Published application
- Kind: A1
- Application number: 14/876,298
- Filed: 2015-10-06
- Published: 2016-09-01
- Earliest claimed: 2009-06-05
- Assignees: 13 Therapeutics, Inc.
- Applicants: 13 Therapeutics, Inc.
- Inventors: Sharon L. McCoy; Steven H. Hefeneider
- Web page: https://patentgrep.com/patent/US20160250320A1

## CPC

- A61K 39/285: Vaccinia virus or variola virus
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/005: from viruses
- C07K 14/07: Vaccinia virus; Variola virus
- C07K 14/47: from mammals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C12N 2710/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media.

## Claims

### Claim at position 1

1-44. (canceled)

### Claim 45

A pharmaceutical peptide composition comprising: a peptide-transducing sequence conjugate, wherein the peptide comprises SEQ ID NO.: 327, SEQ ID NO.: 368, SEQ ID NO.: 352, SEQ ID NO.: 367, or SEQ ID NO.: 353; and wherein the peptide is conjugated to a transducing sequence at the peptide C-terminus; and a pharmaceutically-acceptable excipient, wherein the pharmaceutical composition is in a unit dosage form.

### Claim 46 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the transducing sequence is a poly-arginine sequence.

### Claim 47 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the transducing sequence comprises nine consecutive arginine residues (SEQ ID NO: 379).

### Claim 48 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the transducing sequence consists of nine consecutive arginine residues (SEQ ID NO: 379).

### Claim 49 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein at least one amino acid residue of the transducing sequence is a D-amino acid residue.

### Claim 50 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein all the amino acid residues of the transducing sequence are D-amino acid residues.

### Claim 51 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the peptide is SEQ ID NO.: 327.

### Claim 52 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the peptide is SEQ ID NO.: 368.

### Claim 53 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the peptide is SEQ ID NO.: 352.

### Claim 54 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the peptide is SEQ ID NO.: 367.

### Claim 55 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the peptide is SEQ ID NO.: 353.

### Claim 56 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the peptide-transducing sequence conjugate is SEQ ID NO.: 141.

### Claim 57 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the peptide-transducing sequence conjugate is SEQ ID NO.: 182.

### Claim 58 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the peptide-transducing sequence conjugate is SEQ ID NO.: 166.

### Claim 59 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the peptide-transducing sequence conjugate is SEQ ID NO.: 181.

### Claim 60 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the peptide-transducing sequence conjugate is SEQ ID NO.: 167.

### Claim 61 (depends on 45)

The pharmaceutical peptide composition of claim 45, wherein the pharmaceutical peptide composition is in the form of a drop.

### Claim 62

A method of treating inflammation in an animal in need thereof, the method comprising: administering to the animal in need thereof a therapeutically-effective amount of a peptide-transducing sequence conjugate, wherein the peptide comprises SEQ ID NO.: 327, SEQ ID NO.: 368, SEQ ID NO.: 352, SEQ ID NO.: 367, or SEQ ID NO.: 353; and wherein the peptide is conjugated to a transducing sequence at the peptide C-terminus, wherein the pharmaceutical composition is in a unit dosage form.

### Claim 63

A method of treating hearing impairment in an animal, the method comprising: administering a therapeutically-effective amount of a peptide-transducing sequence conjugate, wherein the peptide comprises SEQ ID NO.: 327, SEQ ID NO.: 368, SEQ ID NO.: 352, SEQ ID NO.: 367, or SEQ ID NO.: 353; and wherein the peptide is conjugated to a transducing sequence at the peptide C-terminus, to an animal having middle and/or inner ear inflammation and reduced hearing.
